Literature DB >> 16540281

Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae.

Calvin C Daniels1, Travis C Briles, Shaper Mirza, Anders P Håkansson, David E Briles.   

Abstract

Of the proteins on the surface of Streptococcus pneumoniae, one of those best able to elicit protection against pneumococcal infection is pneumococcal surface protein A (PspA). Although this protein is attached to the membrane molecule, lipoteichoic acid, which is well beneath the capsule, PspA's ability to inhibit complement deposition and killing by apolactoferrin, suggests that it must have surface exposure. This study provides quantitative data showing that the capsular polysaccharide on types 2 and 3 pneumococci provides little or no masking ability of antibodies to bind PspA. Capsule was even observed to enhance, rather than inhibit the binding of two protective monoclonal antibodies to their epitopes on cell surface PspA. These results with antibodies to PspA are in contrast to binding by antibodies to the phosphocholine (PC) epitope of the lipoteichoic and teichoic acids. The binding of antibody to PC was largely, but not completely, blocked by capsular polysaccharide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540281     DOI: 10.1016/j.micpath.2006.01.007

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  12 in total

1.  Identification of the targets of cross-reactive antibodies induced by Streptococcus pneumoniae colonization.

Authors:  Aoife M Roche; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

2.  Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A.

Authors:  Calvin C Daniels; Kyung-Hyo Kim; Robert L Burton; Shaper Mirza; Melissa Walker; Janice King; Yvette Hale; Patricia Coan; Dong-Kwon Rhee; Moon H Nahm; David E Briles
Journal:  Clin Vaccine Immunol       Date:  2013-08-07

3.  The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.

Authors:  Calvin C Daniels; Patricia Coan; Janice King; Joanetha Hale; Kimberly A Benton; David E Briles; Susan K Hollingshead
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

4.  Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.

Authors:  Naeem Khan; Raies Ahmad Qadri; Devinder Sehgal
Journal:  Clin Vaccine Immunol       Date:  2014-11-19

5.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

6.  The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms.

Authors:  Catherine Hyams; Emilie Camberlein; Jonathan M Cohen; Katie Bax; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

7.  Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition.

Authors:  M Darrieux; E N Miyaji; D M Ferreira; L M Lopes; A P Y Lopes; B Ren; D E Briles; S K Hollingshead; L C C Leite
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

8.  Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine.

Authors:  Reshmi Mukerji; Shaper Mirza; Aoife M Roche; Rebecca W Widener; Christina M Croney; Dong-Kwon Rhee; Jeffrey N Weiser; Alexander J Szalai; David E Briles
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

9.  PcpA Promotes Higher Levels of Infection and Modulates Recruitment of Myeloid-Derived Suppressor Cells during Pneumococcal Pneumonia.

Authors:  Melissa M Walker; Lea Novak; Rebecca Widener; James Aaron Grubbs; Janice King; Joanetha Y Hale; Martina M Ochs; Lisa E Myers; David E Briles; Jessy Deshane
Journal:  J Immunol       Date:  2016-02-01       Impact factor: 5.422

10.  Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal Colonisation.

Authors:  Franziska Voß; Thomas P Kohler; Tanja Meyer; Mohammed R Abdullah; Fred J van Opzeeland; Malek Saleh; Stephan Michalik; Saskia van Selm; Frank Schmidt; Marien I de Jonge; Sven Hammerschmidt
Journal:  Front Immunol       Date:  2018-10-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.